What is JBIO (JBIO) stock price today?

JBIO (JBIO) is currently trading at $21.96, down 1.26% today.

What is JBIO P/E ratio?

JBIO's P/E ratio is -6.16. This is below the market average, suggesting the stock may be undervalued relative to earnings.

What is JBIO return on equity (ROE)?

JBIO's return on equity (ROE) is -38.14%, indicating how efficiently the company generates profit from shareholders' equity. This is below the typical market average of 12-15%.

What is JBIO's market cap?

JBIO has a market capitalization of $716.46M.

NASDAQ · Biotechnology

JBIO (JBIO) Stock

$21.96 -1.26% NASDAQ: JBIO Healthcare

Valuation

Metric	Value
Price	$21.96
Market Cap	$716.46M
P/E Ratio	-6.16
P/B Ratio	2.45
P/S Ratio	0.00
EPS (TTM)	$-4.06
52-Week High	$28.00
52-Week Low	$6.67
Dividend Yield	0.00%

Financials & Margins

Metric	Value
ROE	-38.14%
ROA	-36.29%
ROCE	-34.23%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.00
Current Ratio	19.76

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$0	$0	$0	$0	$0
Operating Profit	$-23.0M	$-53.0M	$-81.0M	$-75.0M	$-114.0M
Net Profit	$-23.0M	$-52.0M	$-76.0M	$-70.0M	$-127.0M
EPS	$-32.96	$-73.67	$-100.38	$-85.26	$-4.06
Op Margin	—	—	—	—	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$175.0M	$135.0M	$127.0M	$80.0M	$350.0M
Total Liabilities	$3.0M	$9.0M	$18.0M	$4.0M	$17.0M
Cash	$54.0M	$22.0M	$23.0M	$34.0M	$88.0M
Borrowings	$1.0M	$1.0M	$1.0M	$0	$1.0M

Latest News

Jade Biosciences to Receive up to $22 Million as Part of Licensing Deal With Paragon Therapeutics MT Newswires · Jul 2, 2026 Is Jade Biosciences, Inc. (JBIO) Stock a Rising Biotech Opportunity in the $20B IgA Nephropathy Market? Insider Monkey · Jun 30, 2026 Jade Biosciences Announces Appointment of Mark Eisner, M.D., M.P.H., to Board of Directors GlobeNewswire · Jun 26, 2026 Jade Biosciences Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares GlobeNewswire · Jun 5, 2026 Jade Biosciences Announces Pricing of Public Offering of Common Stock GlobeNewswire · Jun 4, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-27.0M	$-39.0M	$-57.0M	$-71.0M	$-95.0M
Investing Cash Flow	$-114.0M	$7.0M	$12.0M	$56.0M	$-247.0M
Financing Cash Flow	$0	$0	$0	$0	$0
Net Cash Flow	$50.0M	$-32.0M	$1.0M	$10.0M	$-34.0M
Free Cash Flow	$-28.0M	$-39.0M	$-57.0M	$-71.0M	$-95.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-16.24%
Quick Ratio	14.29
Interest Coverage	—
Return 1Y	125.26%
Return 3Y	-96.61%
Return 5Y	-95.78%

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
ACIU	$2.31	+0.22%	-4.04	$234.59M	0.00%
ALDX	$1.60	+3.23%	-2.77	$96.51M	0.00%
CTNM	$14.16	+2.16%	-6.62	$529.39M	0.00%
GNLX	$2.94	-3.61%	-3.41	$131.83M	0.00%
KYTX	$7.30	-2.54%	-2.49	$443.81M	0.00%

About JBIO

JBIO is led by CEO Tom Frohlich, publicly traded since 2025.

JBIO stock trades at $21.96 with a market capitalization of $716.46M. The stock is valued at a price-to-earnings (P/E) ratio of -6.16, price-to-book of 2.45, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $6.67 and $28.00, and currently trades 21.6% below its 52-week high.

On profitability, JBIO generates a return on equity (ROE) of -38.14%, return on capital employed of -34.23%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

Screens featuring this stock

High ROE Healthcare Stocks Low P/E Healthcare Stocks High Net Margin Healthcare Stocks Dividend Healthcare Stocks Low Debt Healthcare Stocks Nasdaq High ROE Stocks All stock screens

Run Stock Screener Investing Guides